Skip to textbook content
Doctor’s PassportTextbook
TopicsAll topics

Loading topic navigation…

Textbook navigation
TopicsAll topics

Loading topic navigation…
← Psychiatry indexChapter sections
Role and principlesAssessment and patient selectionBaseline assessmentInterventionsTargets, monitoring and follow-upSpecial situationsCommon pitfallsQuestionsSources
Full textbook9 sectionsOpen only what you need
Educational draft · awaiting clinical reviewThe full textbook explains uncertainty but does not replace live national or local guidance, specialist advice, or current prescribing information.

Avoiding iatrogenic harm and fragmented investigation

Psychiatry · UK scope · Sources checked 27 Aug 2026 · Clinical review pending

RapidFull
!
Safety before utilisation control

A care plan designed to reduce repeated investigation must never block assessment of abnormal physiology, a new red flag, overdose, withdrawal, self-harm, abuse or a materially changed presentation.

Action: Assess the immediate problem through the relevant acute pathway, compare it with the documented baseline, communicate why escalation is needed, and update the coordinated plan after the episode so future clinicians can distinguish routine recurrence from urgent change.

Role and principles

Reduce harm from duplicated tests, incidental findings, polypharmacy and contradictory explanations while preserving access to appropriate investigation, urgent care and shared decisions for genuinely new clinical change.

Healthcare can cause harm through radiation, invasive complications, contrast exposure, false positives, incidental findings, adverse drugs, withdrawal and psychological threat. Fragmentation magnifies these effects: each service sees part of the story, repeats exclusionary testing and offers a different explanation. The answer is coordinated proportional care, not a blanket declaration that further assessment is forbidden.

Every proposed investigation begins with a question. Estimate whether the result could distinguish plausible diagnoses and change treatment. Discuss false positives and downstream procedures, especially when pre-test probability is low. A test can be technically accurate yet clinically low value if neither possible result changes the plan. Conversely, a new objective sign or altered pattern creates a new question and may make a previously unnecessary test appropriate.

A useful shared summary lists the symptom chronology, established diagnoses, important negative and positive results, current uncertainty, medicine history, patient concerns, functional goals and red flags. It identifies who coordinates care and when review occurs. Language matters: describe a working formulation and completed evaluation rather than labelling a person as a frequent attender or writing that nothing is wrong.

Assessment and patient selection

Duplicated investigation

The same test is repeated without a changed clinical question, accessible result review or clear explanation of what new information is expected.

Incidental finding cascade

A low-probability test identifies an unrelated abnormality, prompting surveillance or invasive procedures that do not explain the original symptom.

Polypharmacy drift

Medicines accumulate from different services, with overlapping targets, no current benefit review and symptoms caused by adverse effects or withdrawal.

Contradictory formulations

Different clinicians alternately imply serious hidden disease, psychological fabrication or complete normality, increasing uncertainty and repeated help seeking.

Diagnostic overshadowing

A psychiatric, functional or persistent-symptom label causes new objective change, physical disease, abuse or medicine toxicity to be under-assessed.

Red flags requiring action

  • Abnormal vital signs, focal neurology, acute confusion, collapse or a new objective deficit overrides any routine limited-investigation plan.
  • Progressive weight loss, fever, bleeding, mass, severe night symptoms or changed pain requires fresh presentation-specific assessment.
  • Overdose, intoxication, dangerous withdrawal, medication duplication or serious adverse reaction needs urgent medicines and medical review.

Baseline assessment

  1. 01
    Shared-record reviewFirst step
    Why
    Locate previous results, images, specialist reasoning, medicine changes and unresolved recommendations before repeating assessment.
    Interpretation and limitations
    A previous adequate answer avoids duplication; an inaccessible, poor-quality or outdated assessment may leave a genuine focused gap.
  2. 02
    Pre-test question statement
    Why
    Document the suspected condition, estimated likelihood and management consequence of each plausible result before requesting a test.
    Interpretation and limitations
    If neither a positive nor negative result would change care, the test is unlikely to offer net clinical value.
  3. 03
    Medicine reconciliation
    Why
    Compare the record with what the person actually takes, who prescribes it, its indication, benefit, adverse effects and withdrawal risk.
    Interpretation and limitations
    Duplication or limited benefit supports collaborative review, but the sequence and taper reflect pharmacology, duration and patient risk.
  4. 04
    Treatment-burden review
    Why
    Measure appointments, monitoring, travel, cost, self-management tasks and effects on work, care and quality of life.
    Interpretation and limitations
    A clinically reasonable individual intervention may create excessive total burden when combined with every other plan.
  5. 05

Interventions

01Before a testMake investigation purposefulFirst stepA new investigation or referral is being considered for persistent or recurrent symptoms.+
  1. 1Review the chronology, examination, prior results and the person's concern, then state the precise diagnosis or decision the test addresses.
  2. 2Discuss likely benefits, false positives, incidental findings, procedural burdens and the option of planned observation with a safety-net.
  3. 3Request the focused test only when the result can change care, and assign responsibility for explaining and acting on every outcome.
02Care coordinationBuild one accountable planMultiple services, repeated contacts or incompatible recommendations are creating treatment burden.+
  1. 1Agree a named coordinator and produce a concise shared formulation separating established disease, symptom mechanisms and unresolved uncertainty.

Targets, monitoring and follow-up

  • Track duplicated tests, unresolved results, incidental findings and whether every investigation has a named clinician responsible for follow-up.
  • Review total appointment and self-management burden against the person's priorities, function, work and caring responsibilities.
  • Repeat medicine reconciliation after emergency visits, hospital discharge and specialist changes, monitoring benefit, adverse effects and withdrawal.
  • Audit whether new red flags receive normal assessment and whether the care plan is causing delayed diagnosis or barriers to urgent access.
  • Ask whether the person understands the formulation, safety-net and next review, and correct conflicting messages across services promptly.

Special situations

No test is a decision

Choosing observation is active care when reasoning, expected course, review interval and escalation criteria are explicit and shared with the person.

Normal is not explanatory

A normal scan can reduce likelihood of one lesion but rarely explains continuing symptoms; pair the result with a positive formulation and next step.

Incidentalomas need ownership

Someone must tell the person whether an incidental finding matters, arrange any agreed surveillance and prevent it being repeatedly rediscovered as unresolved.

Coordination preserves diagnosis

Continuity makes genuine change easier to recognise because clinicians can compare against a known baseline rather than either retesting everything or dismissing everything.

Burden changes net benefit

A guideline-consistent intervention may become unreasonable when combined with many other tasks, appointments and risks; multimorbidity care prioritises the whole plan.

Common pitfalls

  1. 01

    Using a high-utilisation label as justification for refusing examination or urgent assessment of a changed presentation.

  2. 02

    Repeating tests because previous results are not reviewed, then leaving new incidental findings unexplained and unowned.

  3. 03

    Telling the person that nothing is wrong after excluding only a narrow set of structural diagnoses.

  4. 04

    Stopping several long-term medicines together or withdrawing dependence-forming drugs abruptly to simplify the list.

  5. 05

    Creating a restricted-care plan without the person's involvement, accessible review or explicit exceptions for red flags.

  6. 06

    Referring sequentially to specialties without a coordinator, shared clinical question or responsibility for integrating conclusions.

Practice

Two practice questions

Your practice draft is saved in this browser.

Question 1 of 2
0 correct
PsychiatryOriginal SBA

Purposeful investigation decision

A patient with stable recurrent abdominal discomfort has had two recent adequate normal scans and no new signs. A third scan is proposed because reassurance did not last. What is the best next step?

Choose one answer, then submit
← Rapid synopsisBack to overviewAll Psychiatry topics →
Sources and review status4 sources · checked 27 Aug 2026 · clinical review pending+
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Apply principles in context and verify current guidance when a decision affects care. Source check completed 27 Aug 2026; clinical approval remains outstanding.

  • NICE NG197 shared decision makingBenefits, harms, alternatives, decision support and joint discussion of what matters to the person.
  • NICE NG56 multimorbidity recommendationsCoordination, treatment burden, medicines review and individualised management planning.
  • NICE NG193 chronic pain recommendationsPerson-centred assessment, uncertainty, review and avoiding harmful low-value medicine initiation.
  • NHS England persistent physical symptomsIntegrated physical and psychological care with jointly developed treatment planning.

Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes

Authoring stateComplete draftClinical stateAwaiting reviewJurisdictionUnited Kingdom

Medicine burden requires reconciliation across primary, specialist, urgent and private care. Ask what is actually taken, including over-the-counter and non-prescribed products, and identify sedation, anticholinergic burden, constipation, interactions and overlapping indications. If benefit is unclear, agree a monitored change. Benzodiazepines, opioids, gabapentinoids, antidepressants and other drugs with withdrawal effects may need gradual individualised tapering; abrupt cessation can create new symptoms and emergency attendance.

Shared decision making is a clinical process, not a signature. Explain reasonable options, including watchful waiting, in plain language; explore what matters to the person; and reach or defer a decision with a clear review point. A written safety-net states the expected course, what change matters, who to contact and how urgently. This makes restraint accountable and reversible rather than dismissive.

Key points

  • Before ordering a test, define the clinical question and how a positive, negative or incidental result would alter management.
  • Review shared records and previous results to avoid duplication, while recognising that an old normal test does not exclude new disease.
  • Create a single problem list that distinguishes established disease, persistent symptom mechanisms, unresolved uncertainty and adverse treatment effects.
  • Nominate a coordinating clinician or team and specify what each specialist owns, preventing simultaneous unconnected plans.
  • Explain incidental findings explicitly: whether they are causal, require surveillance or need no further action.
  • Use scheduled review and a written safety-net to reduce crisis-driven testing without denying legitimate access to care.
  • Reconcile medicines across prescribers, identify duplicate or dependence-forming drugs and change one important variable at a time where feasible.
  • Shared decision making includes the option of no test or no treatment, discussed with benefits, harms, uncertainty and the person's goals.
  • Suicidality, self-neglect, coercive control, exploitation or inability to care for dependants requires proportionate mental-health and safeguarding action.
    • Incident and utilisation pattern
    Why
    Map emergency attendance, missed follow-up, conflicting referrals and investigation cascades to find system failures rather than blame the patient.
    Interpretation and limitations
    Repeated crisis care may indicate an inaccessible safety-net, unresolved fear, poor coordination, deterioration or unmet safeguarding need.
    2
    Reconcile medicines, referrals and monitoring, identifying duplication, interactions and which clinician owns each action or result.
  • 3Set scheduled review, functional goals and explicit urgent-change criteria accessible to the person and relevant services.
    • 03DeprescribingReduce harm without abandonmentA medicine has limited benefit, excessive risk or no continuing indication within the person's priorities.+
    1. 1Explain the balance of benefit, harm and withdrawal, ask what the person fears about change and agree the first medicine to review.
    2. 2Use a drug-specific gradual plan when dependence or withdrawal is possible, changing one major variable at a time where clinically feasible.
    3. 3Monitor target symptoms, withdrawal, function and new red flags, pausing or adjusting rather than interpreting difficulty as non-cooperation.